{"id":796779,"date":"2024-12-23T09:04:01","date_gmt":"2024-12-23T14:04:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/renovarocube-receives-approval-of-lumina-project-by-the-eurostars-funding-program\/"},"modified":"2024-12-23T09:04:01","modified_gmt":"2024-12-23T14:04:01","slug":"renovarocube-receives-approval-of-lumina-project-by-the-eurostars-funding-program","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/renovarocube-receives-approval-of-lumina-project-by-the-eurostars-funding-program\/","title":{"rendered":"RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program"},"content":{"rendered":"
\n

\n LUMINA is an Advanced Minimal Residual Disease Detection Platform for Lung Cancer Harnessing the Power of Multi-omics Biomarkers and AI<\/em>\n <\/p>\n

LOS ANGELES and AMSTERDAM, Dec. 23, 2024 (GLOBE NEWSWIRE) — Renovaro Inc. (NASDAQ: RENB),<\/strong> \u00a0a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced its subsidiary RenovaroCube\u00a0(the \u2018Cube\u2019)<\/strong>, a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, together with its consortium partners Flomics Biotech, Uppsala Universitet and Oncodia, received grant funding approval for the Lumina project from the Eurostars funding program after review by an independent expert panel.<\/p>\n

Eurostars is part of the European Partnership on Innovative SMEs (Small and Medium-sized Enterprises). The partnership is co-funded by the European Union through Horizon Europe. Eurostars is the largest international funding program for SMEs wishing to collaborate on R&D projects that create innovative products, processes or services for commercialization, with over \u20ac250M in expected public-private investment each year.<\/p>\n

The Lumina project aims to deliver an advanced Minimal Residual Disease (MRD) detection platform for lung cancer. Harnessing the power of multi-omics biomarkers and AI-driven technology, this platform aims to transform recurrence risk prediction and treatment strategies for millions of patients worldwide.<\/p>\n

\u201cThis award further validates our purpose-built AI platform in facilitating the discovery of biomarkers critical for early cancer detection, monitoring, and treatment personalization,\u201d said David Weinstein, Chief Executive Officer of Renovaro. \u201cIn partnership with leading institutions and companies, including Uppsala University, Oncodia AB, and Flomics Biotech, the Lumina project is focused on improving lung cancer patient survival. Over 5.7 million lung cancer cases are treated or monitored globally each year, and of all curatively treated lung cancer patients, 60% will relapse. Lumina represents a significant opportunity to address this critical issue, and we look forward to continuing work with our partners to bring this product to market.\u201d<\/p>\n

\n A High-Performance Platform for Better Outcomes<\/strong>\n <\/p>\n

The objective of the LUMINA project is to develop a cutting-edge platform designed to provide unparalleled accuracy in detecting minimal residual disease. To achieve this, liquid biopsies combined with multi-omics biomarker technology, represent a revolutionary approach. The LUMINA project\u2019s AI-powered platform capitalizes on this potential, aiming to provide a highly accurate, non-invasive solution that addresses a critical unmet need in lung cancer care.<\/p>\n

\n Collaborative Expertise<\/strong>\n <\/p>\n

The LUMINA project is built on a strong foundation of collaboration with leading institutions and companies, including Uppsala University, Oncodia AB, and Flomics Biotech. These partnerships bring together world-class clinical expertise and a multi-omic approach, leveraging the analysis of cell-free DNA and RNA to ensure the platform\u2019s success.<\/p>\n

\n About\u00a0Renovaro<\/strong><\/p>\n

Renovaro\u00a0https:\/\/renovarogroup.com\/<\/a>\u00a0aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.<\/p>\n

\n About RenovaroCube<\/strong>\n <\/p>\n

RenovaroCube is a pioneer in AI-based molecular diagnostics, committed to revolutionizing healthcare through advanced data analysis. Its platform integrates cutting-edge AI capabilities with state-of-the-art HPC infrastructure to provide unparalleled insights into multi-omic data\u00a0for early detection of diseases based on non-invasive testing using liquid biopsy (blood).<\/p>\n

RenovaroCube\u2019s AI platform is purpose-built to process and analyze\u00a0multi-omic molecular data<\/strong>, facilitating the discovery of biomarkers critical for early cancer detection, monitoring, and treatment personalization. Originally developed for the fintech sector, this platform is being reengineered for healthcare, offering:<\/p>\n